Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545473 | 0.88 | SMN1; SMN2 (0.42) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 | |
| SCHEMBL2551434 | 0.86 | RAB9A (0.39) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 | |
| SCHEMBL2551438 | 0.86 | RAB9A (0.39) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 | |
| SCHEMBL15199675 | 0.80 | NPC1 (0.45) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 | |
| SCHEMBL823364 | 0.73 | NR1H4 (0.44) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 | |
| SCHEMBL12266074 | 0.73 | NPC1 (0.46) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 | |
| SCHEMBL15199676 | 0.72 | NPC1 (0.45) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 | |
| SCHEMBL13572504 | 0.72 | MAPT (0.39) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 | |
| SCHEMBL4277137 | 0.72 | MAPT (0.39) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 | |
| SCHEMBL12265264 | 0.70 | NPC1 (0.44) | RAB9ASMN1; SMN2HPGDL3MBTL1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3235818-A2 | COMPOUNDS FOR THE TREATMENT OF HIV | Critical Outcome Technologies, Inc. (CA) | 2017-10-25 | — | — | EP | disclosed |
| EP-3235818-A2 | COMPOUNDS FOR THE TREATMENT OF HIV | Critical Outcome Technologies, Inc. (CA) | 2017-10-25 | — | — | EP | disclosed |
| EP-2552915-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | CRITICAL OUTCOME TECH INC (CA) | 2017-07-19 | — | — | EP | disclosed |
| EP-2552915-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | CRITICAL OUTCOME TECH INC (CA) | 2017-07-19 | — | — | EP | disclosed |
| US-9624220-B2 | Compounds and method for treatment of HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2017-04-18 | — | — | US | disclosed |
| US-9624220-B2 | Compounds and method for treatment of HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2017-04-18 | — | — | US | disclosed |
| US-9624220-B2 | Compounds and method for treatment of HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2017-04-18 | — | — | US | disclosed |
| US-20160333010-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECH INC (CA) | 2016-11-17 | — | — | US | disclosed |
| US-20160333010-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECH INC (CA) | 2016-11-17 | — | — | US | disclosed |
| US-20160333010-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECH INC (CA) | 2016-11-17 | — | — | US | disclosed |
| US-20150183782-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | MORGAN STANLEY SENIOR FUNDING, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8987272-B2 | Compounds and method for treatment of HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2015-03-24 | — | — | US | disclosed |
| US-8987272-B2 | Compounds and method for treatment of HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2015-03-24 | — | — | US | disclosed |
| US-8987272-B2 | Compounds and method for treatment of HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2015-03-24 | — | — | US | disclosed |
| US-20130217693-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| US-20130217693-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| US-20130217693-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| EP-2552915-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | Critical Outcome Technologies, Inc. (CA) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011120153-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011120153-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333010-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | NNT, CCR5, XDH | RAB9A 3745/4885SMN1; SMN2 1940/4885HPGD 1082/4885 |
| US-20130217693-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | NNT, CCR5, XDH | RAB9A 3745/4885SMN1; SMN2 1940/4885HPGD 1082/4885 |
| US-20150183782-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | NNT, CCR5, XDH | RAB9A 3745/4885SMN1; SMN2 1940/4885HPGD 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.